Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer — ScienceDaily
CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive metastatic breast cancer has historically been one of the most aggressive forms of the disease. “In CLEOPATRA we evaluated whether dual HER2 blockade by combining the antibody pertuzumab with trastuzumab and chemotherapy would help people live longer (overall survival, OS) or live longer without their disease worsening (progression-free survival, PFS),” explains lead author Dr Sandra Swain from Washington Hospital Center, Washington, USA…